Trial · NCT06860269
A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia
NCT06860269, Phase 2, Phase 3, Recruiting, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia. Trials, record NCT06860269. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06860269
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia
- NCT number
- NCT06860269
- Status
- Recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 1,200 participants, estimated
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
Randomization + Blinatumomab + chemotherapy, Randomization + Standard frontline T-ALL chemotherapy backbone, Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone, Randomization + Blinatumomab + Ponatinib + chemotherapy, Randomization 1 + Allo HSCT, Randomization 2 + Allo HSCT
- First posted
- 2025-03-06
- Last updated
- 2026-02-10
Source ClinicalTrials.gov
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall survival | At 5 years | For GRAAL-2024/B HR patients (phase 3) |
| Primary | Overall survival | At 5 years | For GRAAL-2024/B SR patients (phase 2) |
| Primary | Event-Free Survival | At 5 years | For GRAAL-2024/T patients (phase 3) |
| Primary | Overall survival | At 5 years | For GRAAPH-2024 patients (phase 3) - Phpos ALL |
| Secondary | Overall survival | At 5 years | in the T-ALL/LL cohorts |
| Secondary | Event Free Survival | At 5 years | |
| Secondary | Relapse Free Survival | At 5 years | |
| Secondary | Hematological complete response rate | At 45 days | After induction |
| Secondary | Hematological complete response rate | At 4 months | After consolidation |
| Secondary | Measurable residual disease (MRD) response level | At inclusion | (IG/TR and BCR::ABL1 markers) at diagnosis |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06860269
GET https://conductscience.org/api/trials/v1/NCT06860269/registered?page=2